Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children

Pediatr Infect Dis J. 2004 Aug;23(8):769-73. doi: 10.1097/01.inf.0000134314.65398.bf.

Abstract

A human immunodeficiency virus-infected boy with Scedosporium apiospermum otomastoiditis and a girl with diabetes mellitus and Mucor sinusitis and orbital cellulitis had life-threatening disease progression despite antifungal treatment. Interferon-gamma and granulocyte-macrophage or granulocyte colony-stimulating factor were added, with good functional outcome in both children. Adjunctive therapy with interferon-gamma, granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor can be considered for refractory invasive fungal infections.

Publication types

  • Case Reports

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Child
  • Diabetes Mellitus, Type 1 / complications
  • Drug Resistance, Fungal
  • Drug Therapy, Combination
  • Granulocyte Colony-Stimulating Factor / administration & dosage
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage
  • Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use
  • HIV Infections / complications
  • Humans
  • Immunocompromised Host
  • Interferon-gamma / therapeutic use*
  • Male
  • Mucor / pathogenicity
  • Mucormycosis / drug therapy*
  • Mucormycosis / pathology
  • Mycetoma / drug therapy*
  • Mycetoma / pathology
  • Scedosporium / pathogenicity
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Granulocyte Colony-Stimulating Factor
  • Interferon-gamma
  • Granulocyte-Macrophage Colony-Stimulating Factor